Showing results (1-10 of 55) with videos related to

Sort By:
Pageof 6
Internal and Emergency Medicine|February 14, 2017
Complement blockade in ANCA-associated vasculitis: an index case, current concepts and future perspectivesLucio Manenti, Maria Letizia Urban, Federica Maritati, et al.
International Journal of Environmental Research and Public Health|March 11, 2023
Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic ReviewGiuseppina Folesani, Maricla Galetti, Pier Giorgio Petronini, et al.
La Medicina Del Lavoro|August 27, 2024
Critical Issues in Assessing Occupational Exposure to Diesel Dust ExhaustGiuseppina Folesani, Monica Gherardi, Maricla Galetti, et al.
Expert Review of Respiratory Medicine|August 1, 2022
Interaction between occupational radon exposure and tobacco smoke: a systematic reviewGiuseppina Folesani, Maricla Galetti, Silvia Ranzieri, et al.
Metallomics : Integrated Biometal Science|November 15, 2016
Autophagy and apoptosis: studies on the effects of bisthiosemicarbazone copper(ii) complexes on p53 and p53-null tumour cell linesFranco Bisceglie, Rossella Alinovi, Silvana Pinelli, et al.
Current Medicinal Chemistry|September 3, 2024
Myrtleciclib, a CDK4/6/9 Inhibitor for the Treatment of Aggressive CancersDavide De Forni, Barbara Poddesu, Giulia Cugia, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|November 10, 2016
Post-translational modified proteins are biomarkers of autoimmune-processes: NETosis and the inflammatory-autoimmunity connectionMaurizio Bruschi, Andrea Petretto, Roberta Bertelli, et al.
Oncogene|September 14, 2004
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell lineAndrea Cavazzoni, Pier Giorgio Petronini, Maricla Galetti, et al.
Scientific Reports|September 12, 2019
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cellsDaniele Cretella, Claudia Fumarola, Mara Bonelli, et al.
Pageof 6